(+)-catechin multiple interactions ISO RGD:1323687 6480464 [Catechin co-treated with Grape Seed Proanthocyanidins] results in increased expression of POLE2 mRNA CTD PMID:24763279 (-)-epigallocatechin 3-gallate multiple interactions ISO RGD:1323687 6480464 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of POLE2 mRNA CTD PMID:22079256 (-)-epigallocatechin 3-gallate decreases expression ISO RGD:1323687 6480464 epigallocatechin gallate results in decreased expression of POLE2 mRNA CTD PMID:22079256 1-naphthyl isothiocyanate increases expression EXP 6480464 1-Naphthylisothiocyanate results in increased expression of POLE2 mRNA CTD PMID:30723492 17alpha-ethynylestradiol multiple interactions ISO RGD:1323688 6480464 [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of POLE2 mRNA CTD PMID:17942748 17beta-estradiol increases expression ISO RGD:1323687 6480464 Estradiol results in increased expression of POLE2 mRNA CTD PMID:19167446 , PMID:25321415 17beta-estradiol multiple interactions EXP 6480464 [bisphenol A co-treated with Estradiol] results in increased expression of POLE2 mRNA CTD PMID:26496021 2,2',4,4',5,5'-hexachlorobiphenyl multiple interactions ISO RGD:1323688 6480464 [2 more ... CTD PMID:25510870 2,2',5,5'-tetrachlorobiphenyl multiple interactions ISO RGD:1323688 6480464 [2 more ... CTD PMID:25510870 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:1323688 6480464 [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of POLE2 mRNA CTD PMID:17942748 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:1323687 6480464 Tetrachlorodibenzodioxin results in decreased expression of POLE2 mRNA CTD PMID:20106945 , PMID:21802500 2,3-dimethoxynaphthalene-1,4-dione increases expression ISO RGD:1323687 6480464 2 more ... CTD PMID:19031421 2-methylcholine affects expression ISO RGD:1323687 6480464 beta-methylcholine affects the expression of POLE2 mRNA CTD PMID:21179406 3-methylcholanthrene increases expression ISO RGD:1323688 6480464 Methylcholanthrene results in increased expression of POLE2 mRNA CTD PMID:20713471 4-(ethoxymethylene)-2-phenyloxazol-5-one increases expression ISO RGD:1323688 6480464 Oxazolone results in increased expression of POLE2 mRNA CTD PMID:21404309 5-fluorouracil affects response to substance ISO RGD:1323687 6480464 POLE2 protein affects the susceptibility to Fluorouracil CTD PMID:16217747 acetamide increases expression EXP 6480464 acetamide results in increased expression of POLE2 mRNA CTD PMID:31881176 acrylamide increases expression EXP 6480464 Acrylamide results in increased expression of POLE2 mRNA CTD PMID:28959563 aflatoxin B1 increases expression ISO RGD:1323688 6480464 Aflatoxin B1 results in increased expression of POLE2 mRNA CTD PMID:19770486 aflatoxin B1 decreases expression ISO RGD:1323687 6480464 Aflatoxin B1 results in decreased expression of POLE2 mRNA CTD PMID:21641981 aflatoxin M1 decreases expression ISO RGD:1323687 6480464 Aflatoxin M1 results in decreased expression of POLE2 mRNA CTD PMID:30928695 all-trans-retinoic acid decreases expression ISO RGD:1323687 6480464 Tretinoin results in decreased expression of POLE2 mRNA CTD PMID:16054129 more ... amphetamine decreases expression EXP 6480464 Amphetamine results in decreased expression of POLE2 mRNA CTD PMID:30779732 aristolochic acid A decreases expression ISO RGD:1323687 6480464 aristolochic acid I results in decreased expression of POLE2 mRNA CTD PMID:33212167 arsenite(3-) multiple interactions ISO RGD:1323687 6480464 arsenite promotes the reaction [G3BP1 protein binds to POLE2 mRNA] CTD PMID:32406909 atrazine decreases expression ISO RGD:1323687 6480464 Atrazine results in decreased expression of POLE2 mRNA CTD PMID:22378314 azathioprine decreases expression ISO RGD:1323687 6480464 Azathioprine results in decreased expression of POLE2 mRNA CTD PMID:22623647 benzo[a]pyrene decreases expression ISO RGD:1323688 6480464 Benzo(a)pyrene results in decreased expression of POLE2 mRNA CTD PMID:17942131 , PMID:19770486 benzo[a]pyrene increases expression ISO RGD:1323687 6480464 Benzo(a)pyrene results in increased expression of POLE2 mRNA CTD PMID:32234424 benzo[a]pyrene increases methylation ISO RGD:1323687 6480464 Benzo(a)pyrene results in increased methylation of POLE2 promoter CTD PMID:27901495 benzo[a]pyrene decreases expression ISO RGD:1323687 6480464 Benzo(a)pyrene results in decreased expression of POLE2 mRNA CTD PMID:21632981 , PMID:21802500 benzo[a]pyrene diol epoxide I decreases expression ISO RGD:1323687 6480464 7 more ... CTD PMID:20382639 bis(2-chloroethyl) sulfide decreases expression ISO RGD:1323687 6480464 Mustard Gas results in decreased expression of POLE2 mRNA CTD PMID:25102026 bisphenol A multiple interactions EXP 6480464 [bisphenol A co-treated with Estradiol] results in increased expression of POLE2 mRNA CTD PMID:26496021 bisphenol A decreases expression ISO RGD:1323687 6480464 bisphenol A results in decreased expression of POLE2 mRNA CTD PMID:29275510 bisphenol A decreases expression EXP 6480464 bisphenol A results in decreased expression of POLE2 mRNA CTD PMID:25181051 , PMID:34947998 calcitriol decreases expression ISO RGD:1323687 6480464 Calcitriol results in decreased expression of POLE2 mRNA CTD PMID:21592394 calcitriol multiple interactions ISO RGD:1323687 6480464 [Testosterone co-treated with Calcitriol] results in decreased expression of POLE2 mRNA CTD PMID:21592394 cannabidiol decreases expression ISO RGD:1323687 6480464 Cannabidiol results in decreased expression of POLE2 mRNA CTD PMID:36519830 carbon nanotube increases expression ISO RGD:1323688 6480464 Nanotubes more ... CTD PMID:25554681 chloroethene increases expression ISO RGD:1323688 6480464 Vinyl Chloride results in increased expression of POLE2 mRNA CTD PMID:18579281 choline multiple interactions ISO RGD:1323688 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of POLE2 mRNA CTD PMID:20938992 cisplatin multiple interactions ISO RGD:1323687 6480464 Cisplatin inhibits the reaction [Piroxicam results in increased expression of POLE2 mRNA] CTD PMID:21858171 cisplatin decreases expression EXP 6480464 Cisplatin results in decreased expression of POLE2 mRNA CTD PMID:22023808 clofibrate decreases expression EXP 6480464 Clofibrate results in decreased expression of POLE2 mRNA CTD PMID:15585944 cobalt dichloride decreases expression ISO RGD:1323687 6480464 cobaltous chloride results in decreased expression of POLE2 mRNA CTD PMID:19376846 copper atom multiple interactions ISO RGD:1323687 6480464 [NSC 689534 binds to Copper] which results in decreased expression of POLE2 mRNA CTD PMID:20971185 copper(0) multiple interactions ISO RGD:1323687 6480464 [NSC 689534 binds to Copper] which results in decreased expression of POLE2 mRNA CTD PMID:20971185 copper(II) sulfate decreases expression ISO RGD:1323687 6480464 Copper Sulfate results in decreased expression of POLE2 mRNA CTD PMID:19549813 coumestrol multiple interactions ISO RGD:1323687 6480464 [Coumestrol co-treated with 2 more ... CTD PMID:19167446 coumestrol increases expression ISO RGD:1323687 6480464 Coumestrol results in increased expression of POLE2 mRNA CTD PMID:19167446 cyclosporin A decreases expression ISO RGD:1323688 6480464 Cyclosporine results in decreased expression of POLE2 mRNA CTD PMID:17942131 cyclosporin A decreases expression ISO RGD:1323687 6480464 Cyclosporine results in decreased expression of POLE2 mRNA CTD PMID:20106945 more ... dibutyl phthalate decreases expression ISO RGD:1323688 6480464 Dibutyl Phthalate results in decreased expression of POLE2 mRNA CTD PMID:17361019 , PMID:21266533 dicrotophos decreases expression ISO RGD:1323687 6480464 dicrotophos results in decreased expression of POLE2 mRNA CTD PMID:28302478 dimethylarsinic acid increases expression ISO RGD:1323688 6480464 Cacodylic Acid results in increased expression of POLE2 mRNA CTD PMID:17441966 dimethylarsinous acid decreases expression ISO RGD:1323687 6480464 dimethylarsinous acid results in decreased expression of POLE2 mRNA CTD PMID:20886546 dioxygen decreases expression ISO RGD:1323687 6480464 Oxygen deficiency results in decreased expression of POLE2 mRNA CTD PMID:26516004 dioxygen multiple interactions ISO RGD:1323688 6480464 [NFE2L2 protein affects the susceptibility to Oxygen] which affects the expression of POLE2 mRNA CTD PMID:30529165 Enterolactone multiple interactions ISO RGD:1323687 6480464 [Coumestrol co-treated with 2, 3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of POLE2 mRNA CTD PMID:19167446 folic acid multiple interactions ISO RGD:1323688 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of POLE2 mRNA CTD PMID:20938992 folic acid multiple interactions ISO RGD:1323687 6480464 [Folic Acid deficiency co-treated with Methotrexate] results in decreased expression of POLE2 mRNA CTD PMID:24657277 formaldehyde decreases expression ISO RGD:1323687 6480464 Formaldehyde results in decreased expression of POLE2 mRNA CTD PMID:23649840 fragrance increases expression ISO RGD:1323687 6480464 Perfume results in increased expression of POLE2 mRNA CTD PMID:24768652 furan increases expression EXP 6480464 furan results in increased expression of POLE2 mRNA CTD PMID:25539665 gentamycin decreases expression EXP 6480464 Gentamicins results in decreased expression of POLE2 mRNA CTD PMID:33387578 glycine betaine decreases expression EXP 6480464 Betaine results in decreased expression of POLE2 mRNA CTD PMID:26391144 glyphosate decreases expression ISO RGD:1323687 6480464 glyphosate results in decreased expression of POLE2 mRNA CTD PMID:31295307 hydrogen peroxide decreases expression ISO RGD:1323687 6480464 Hydrogen Peroxide results in decreased expression of POLE2 mRNA CTD PMID:12414654 hydroquinone O-beta-D-glucopyranoside increases expression ISO RGD:1323687 6480464 Arbutin results in increased expression of POLE2 mRNA CTD PMID:17103032 irinotecan increases response to substance ISO RGD:1323687 6480464 POLE2 protein results in increased susceptibility to Irinotecan CTD PMID:16734730 isobutanol multiple interactions ISO RGD:1323687 6480464 [[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of POLE2 mRNA CTD PMID:29432896 ivermectin decreases expression ISO RGD:1323687 6480464 Ivermectin results in decreased expression of POLE2 protein CTD PMID:32959892 ketamine decreases expression EXP 6480464 Ketamine results in decreased expression of POLE2 mRNA CTD PMID:20080153 L-methionine multiple interactions ISO RGD:1323688 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of POLE2 mRNA CTD PMID:20938992 Lasiocarpine increases expression ISO RGD:1323687 6480464 lasiocarpine results in increased expression of POLE2 mRNA CTD PMID:32234424 leflunomide decreases expression ISO RGD:1323687 6480464 leflunomide results in decreased expression of POLE2 mRNA CTD PMID:28988120 lidocaine increases expression EXP 6480464 Lidocaine results in increased expression of POLE2 mRNA CTD PMID:35283115 lucanthone decreases expression ISO RGD:1323687 6480464 Lucanthone results in decreased expression of POLE2 mRNA CTD PMID:21148553 menadione decreases expression ISO RGD:1323687 6480464 Vitamin K 3 results in decreased expression of POLE2 mRNA CTD PMID:12414654 methotrexate multiple interactions ISO RGD:1323687 6480464 [Folic Acid deficiency co-treated with Methotrexate] results in decreased expression of POLE2 mRNA CTD PMID:24657277 methotrexate decreases expression ISO RGD:1323687 6480464 Methotrexate results in decreased expression of POLE2 mRNA CTD PMID:24657277 methylisothiazolinone decreases expression ISO RGD:1323687 6480464 2-methyl-4-isothiazolin-3-one results in decreased expression of POLE2 mRNA CTD PMID:31629900 nickel atom increases expression ISO RGD:1323687 6480464 Nickel results in increased expression of POLE2 mRNA CTD PMID:25583101 nitrofen decreases expression EXP 6480464 nitrofen results in decreased expression of POLE2 mRNA CTD PMID:33484710 oxaliplatin multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in decreased expression of POLE2 mRNA CTD PMID:25729387 oxaliplatin decreases expression EXP 6480464 oxaliplatin results in decreased expression of POLE2 mRNA CTD PMID:25729387 palbociclib decreases expression ISO RGD:1323687 6480464 palbociclib results in decreased expression of POLE2 mRNA CTD PMID:22869556 paracetamol decreases expression ISO RGD:1323688 6480464 Acetaminophen results in decreased expression of POLE2 mRNA CTD PMID:17585979 , PMID:17942131 paracetamol increases expression EXP 6480464 Acetaminophen results in increased expression of POLE2 mRNA CTD PMID:33387578 paracetamol decreases expression ISO RGD:1323687 6480464 Acetaminophen results in decreased expression of POLE2 mRNA CTD PMID:29067470 paracetamol increases expression ISO RGD:1323687 6480464 Acetaminophen results in increased expression of POLE2 mRNA CTD PMID:22230336 PCB138 multiple interactions ISO RGD:1323688 6480464 [2 more ... CTD PMID:25510870 phenethyl isothiocyanate decreases expression ISO RGD:1323687 6480464 phenethyl isothiocyanate results in decreased expression of POLE2 mRNA CTD PMID:26678675 phenobarbital increases expression ISO RGD:1323688 6480464 Phenobarbital results in increased expression of POLE2 mRNA CTD PMID:23091169 phorbol 13-acetate 12-myristate increases expression ISO RGD:1323687 6480464 Tetradecanoylphorbol Acetate results in increased expression of POLE2 mRNA CTD PMID:19031421 picoxystrobin increases expression ISO RGD:1323687 6480464 picoxystrobin results in increased expression of POLE2 mRNA CTD PMID:33512557 pirinixic acid increases expression ISO RGD:1323688 6480464 pirinixic acid results in increased expression of POLE2 mRNA CTD PMID:17950772 pirinixic acid multiple interactions ISO RGD:1323688 6480464 PPARA protein promotes the reaction [pirinixic acid results in increased expression of POLE2 mRNA] CTD PMID:17950772 piroxicam increases expression ISO RGD:1323687 6480464 Piroxicam results in increased expression of POLE2 mRNA CTD PMID:21858171 piroxicam multiple interactions ISO RGD:1323687 6480464 Cisplatin inhibits the reaction [Piroxicam results in increased expression of POLE2 mRNA] CTD PMID:21858171 potassium chromate decreases expression ISO RGD:1323687 6480464 potassium chromate(VI) results in decreased expression of POLE2 mRNA CTD PMID:22079256 potassium chromate multiple interactions ISO RGD:1323687 6480464 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of POLE2 mRNA CTD PMID:22079256 pravastatin affects expression ISO RGD:1323688 6480464 Pravastatin affects the expression of POLE2 mRNA CTD PMID:27225895 pravastatin decreases expression EXP 6480464 Pravastatin results in decreased expression of POLE2 mRNA CTD PMID:27225895 quercetin decreases expression ISO RGD:1323687 6480464 Quercetin results in decreased expression of POLE2 mRNA CTD PMID:21632981 resveratrol multiple interactions ISO RGD:1323687 6480464 [Coumestrol co-treated with resveratrol] results in increased expression of POLE2 mRNA CTD PMID:19167446 rotenone increases expression ISO RGD:1323687 6480464 Rotenone results in increased expression of POLE2 mRNA CTD PMID:18191903 sodium arsenite increases expression ISO RGD:1323687 6480464 sodium arsenite results in increased expression of POLE2 mRNA CTD PMID:34032870 sodium dichromate increases expression EXP 6480464 sodium bichromate results in increased expression of POLE2 mRNA CTD PMID:22110744 sunitinib decreases expression ISO RGD:1323687 6480464 Sunitinib results in decreased expression of POLE2 mRNA CTD PMID:31533062 tert-butyl hydroperoxide decreases expression ISO RGD:1323687 6480464 tert-Butylhydroperoxide results in decreased expression of POLE2 mRNA CTD PMID:12414654 testosterone multiple interactions ISO RGD:1323687 6480464 [Testosterone co-treated with Calcitriol] results in decreased expression of POLE2 mRNA CTD PMID:21592394 testosterone decreases expression ISO RGD:1323687 6480464 Testosterone results in decreased expression of POLE2 mRNA CTD PMID:21592394 tetrachloromethane affects expression ISO RGD:1323688 6480464 Carbon Tetrachloride affects the expression of POLE2 mRNA CTD PMID:17484886 tetrachloromethane increases expression ISO RGD:1323688 6480464 Carbon Tetrachloride results in increased expression of POLE2 mRNA CTD PMID:31919559 thapsigargin decreases expression ISO RGD:1323687 6480464 Thapsigargin results in decreased expression of POLE2 mRNA CTD PMID:22378314 thioacetamide increases expression EXP 6480464 Thioacetamide results in increased expression of POLE2 mRNA CTD PMID:23411599 , PMID:34492290 topotecan decreases expression EXP 6480464 Topotecan results in decreased expression of POLE2 mRNA CTD PMID:25729387 topotecan multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in decreased expression of POLE2 mRNA CTD PMID:25729387 Tributyltin oxide decreases expression ISO RGD:1323688 6480464 bis(tri-n-butyltin)oxide results in decreased expression of POLE2 mRNA CTD PMID:17942131 trimellitic anhydride increases expression ISO RGD:1323688 6480464 trimellitic anhydride results in increased expression of POLE2 mRNA CTD PMID:19042947 troglitazone decreases expression ISO RGD:1323687 6480464 troglitazone results in decreased expression of POLE2 mRNA CTD PMID:19140230 tungsten increases expression ISO RGD:1323688 6480464 Tungsten results in increased expression of POLE2 mRNA CTD PMID:30912803 urethane decreases expression ISO RGD:1323687 6480464 Urethane results in decreased expression of POLE2 mRNA CTD PMID:28818685 valproic acid affects expression ISO RGD:1323687 6480464 Valproic Acid affects the expression of POLE2 mRNA CTD PMID:25979313 zaragozic acid A decreases expression ISO RGD:1323688 6480464 squalestatin 1 results in decreased expression of POLE2 mRNA CTD PMID:27225895 zaragozic acid A decreases expression EXP 6480464 squalestatin 1 results in decreased expression of POLE2 mRNA CTD PMID:27225895